DRD2 and drug-induced dyskinesia: However, long‐term use of l‐DOPA leads to a gradual loss of drug efficacy and side effects such as motor fluctuations and dyskinesia.[1] An attractive alternative to targeting only the dopamine receptors is to consider the network of G‐protein‐coupled receptors (GPCRs) in the basal ganglia controlling movement, which includes the A2A adenosine receptor.[12] A compound with the ability to interact with both the A2A adenosine receptor (A2AAR) and the D2 dopamine receptor (D2R) could delay progression of the disease and treat the symptoms.